Achaogen, Inc. reported consolidated earnings results for the fourth quarter and full year ended December 31, 2017. For the quarter, the company reported contract revenue of $1,869,000 compared to $10,734,000 a year ago. Loss from operations was $42,104,000 compared to $12,062,000 a year ago. Net loss was $36,382,000 or $0.98 per diluted share compared to $29,724,000 or $1.04 per diluted share a year ago. The decrease in contract revenue during the fourth quarter and 2017 was primarily due to lower Biomedical Advanced Research and Development Authority (BARDA) contract revenues. As anticipated, fourth quarter revenue decreased by $8.9 million compared to the same period last year due to the successful completion of all funded activities and expenditure in BARDA contract for plazomicin development. For the year, the company reported contract revenue of $11,175,000 compared to $41,773,000 a year ago. Loss from operations was $126,326,000 compared to $49,348,000 a year ago. Net loss was $125,618,000 or $3.17 per basic and diluted share compared to $71,227,000 or $3.00 per basic and diluted share a year ago.